Efficacy of interferon-therapy for prevention of developing and progressing cataract after surgical treatment of primary glaucoma
DOI:
https://doi.org/10.31288/oftalmolzh201321518Keywords:
primary glaucoma, surgical treatment, complication, cataract, interferontherapyAbstract
The results of the interferontherapy efficiency after antiglaucomatous surgery (sinustrabeculectomy) for the cataract development and progression prophylaxis is shown in this article. It was stated statistically significant, that the interferontherapy allowed to reduce the frequency of hemorragic and inflammatory complications
in postoperative early stage. The interferontherapy was used in preoperative and postoperative treatment. It was stated, that the frequency of cataract development and progression was reduced twice in 3 and 6 month after surgery treatment.
References
1.Алексеев И. Б. Новая непроникающая операция - экстернализация склерального синуса с увеосклеральным аутодренированием в лечении больных пер-вичной открытоугольной глаукомой/ И. Б. Алексеев, Л. К. Мошетова, А. А. Зубкова // Глаукома. - 2012. - № 2. - С. 44- 49.
2.Павлюченко К. П. Особенности помутнений хрусталика после различных видов антиглаукоматозных операций / К. П. Павлюченко, С. Ю. Могилевский, B.О. Пенчук // Проблеми первинної глаукоми та судинної патології органа зору: наук. - практ. конф. з міжнародною участю: тези доп. - Запоріжжя, 12-13 квітня 2012року. - С. 196- 197.
3.Павлюченко К. П. Прогрессирование катаракты после различных видов антиглаукоматозных операций / К. П. Павлюченко, В. О. Пенчук // Актуальні питання медичної науки та практики: зб. наук. праць. - Запо¬рожжя. - Вип. 75, книга 2. - 2009. - С.82- 86.
4.Павлюченко К. П. Факторы риска развития катаракты после антиглаукоматозных операций / К. П. Павлюченко, С. Ю. Могилевский, В. О. Пенчук // XII съезд офтальмологов Украины: тез. докл. - Одесса, 26-28 мая 2010 года. - С. 126- 127.
5.Пат. 57898 Україна, МПК (2011.01) A61F9/007 Спосіб прогнозування прогресування або розвитку катаракти після антиглаукоматозної операції / Павлюченко К. П., Пенчук В. О., Могілевський С. Ю., Заявл. 30.11.2010; опубл. 10.03.2011, Бюл. № 5.
10.King Anthony J. Treating patients presenting with advanced glaucoma - should we reconsider current practice? / J. Anthony King, E. Richard Stead, P. Alan Rotchford // Br. J Ophthalmol. - 2011. - Vol. 95. - P. 1185- 1192.https://doi.org/10.1136/bjo.2010.188128
11.P. Molecular mechanisms of the anti-inflammatory functions of interferons / P., I., B. // Immunobiology. - 2007. Vol. 212 (9-10). - P. 895- 901.https://doi.org/10.1016/j.imbio.2007.09.011
12.Paire V. Effectiveness of interferon alpha in the treatment of uveitis macular edema refractory to corticosteroid and/ or immunosuppressive treatment / V. Paire, O. Lebreton, M. Weber // J. Fr. Ophtalmol. - 2010. - Mar. 33 (3). - P. 152- 162.https://doi.org/10.1016/j.jfo.2010.01.008
13.Rashmi G Mathew The silent enemy: a review of cata¬ract in relation to glaucoma and trabeculectomy surgery / Rashmi G Mathew, Ian E Murdoch // Br. J. Ophthalmol. - 2011. - Vol. 95. - P. 1350- 1354.https://doi.org/10.1136/bjo.2010.194811
14.Siren V. Alpha- and gamma-interferon inhibit plasmino-gen activator inhibitor-1 gene expression in human retinal pigment epithelial cells./ V. Siriin, I. Immonen, K. Can-tell [et al.] // Ophthalmic Res. - 1994. - Vol. 26 (1). - P. 1-7.https://doi.org/10.1159/000267367
15.The AGIS Investigators. The Advanced Glaucoma Intervention Study, 8: Risk of cataract formation after trabeculectomy // Arch Ophthalmol. - 2001. - Vol. 119. - 1771-1780.https://doi.org/10.1001/archopht.119.12.1771
16.Valerie Touitou Interferon-a2a and Vogt-Koyanagi-Harada disease: a double-edged sword? / Valerie Touitou, Damien Sene, Christine Fardeau [et al.] // International Ophthalmology. - 2007. - Vol. 27, Issue 2-3. - P. 211-215.https://doi.org/10.1007/s10792-007-9040-2
17.Wenhua W. Clinical Study of Interferon treatment of early scarring in filtering bleb / W. Wenhua // Eye Science. - 2011. - Vol. 26. - P. 197- 200.
18.Zhongqiu L. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery / L. Zhongqiu, Tine Van Bergen, Sara Van de Veire [et al.] // Invest. Ophthalmol. Vis. Sci. - 2009. - Vol. 50, № 11. - P. 5217- 5225.https://doi.org/10.1167/iovs.08-2662
19.Zofia von Marschall Effects of Interferon Alpha on Vas¬cular Endothelial Growth Factor Gene Transcription and Tumor Angiogenesis / Zofia von Marschall, Arne Scholz, Thorsten Cramer [et al.] // Journal of the National Cancer Institute. - 2003. - Vol. 95, № 6. - P. 437-448.https://doi.org/10.1093/jnci/95.6.437
Downloads
Published
Issue
Section
License
Copyright (c) 2013 К. П. Павлюченко, С. Ю. Могилевский, В. О. Пенчук
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
